home / stock / lptx / lptx quote
Last: | $2 |
---|---|
Change Percent: | -2.73% |
Open: | $1.88 |
Close: | $2 |
High: | $2.01 |
Low: | $1.8001 |
Volume: | 136,335 |
Last Trade Date Time: | 07/05/2024 03:00:00 am |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$2 | $1.88 | $2 | $2.01 | $1.8001 | 136,335 | 07-05-2024 |
$1.83 | $1.72 | $1.83 | $1.84 | $1.7001 | 69,582 | 07-04-2024 |
$1.83 | $1.72 | $1.83 | $1.84 | $1.7001 | 69,582 | 07-03-2024 |
$1.69 | $1.86 | $1.69 | $1.87 | $1.68 | 168,790 | 07-02-2024 |
$1.87 | $1.95 | $1.87 | $2 | $1.85 | 123,298 | 07-01-2024 |
$1.96 | $1.76 | $1.96 | $1.975 | $1.75 | 233,510 | 06-28-2024 |
$1.77 | $1.75 | $1.77 | $1.795 | $1.69 | 117,440 | 06-27-2024 |
$1.76 | $1.82 | $1.76 | $1.89 | $1.7 | 141,474 | 06-26-2024 |
$1.82 | $1.88 | $1.82 | $1.95 | $1.82 | 57,817 | 06-25-2024 |
$1.88 | $1.91 | $1.88 | $1.96 | $1.86 | 95,945 | 06-24-2024 |
$1.92 | $2.01 | $1.92 | $2.03 | $1.92 | 486,875 | 06-21-2024 |
$1.96 | $1.93 | $1.96 | $2.01 | $1.93 | 111,297 | 06-20-2024 |
$1.94 | $2.03 | $1.94 | $2.065 | $1.93 | 115,611 | 06-19-2024 |
$1.94 | $2.03 | $1.94 | $2.065 | $1.93 | 115,611 | 06-18-2024 |
$2.07 | $2.1 | $2.07 | $2.13 | $2.0238 | 86,649 | 06-17-2024 |
$2.11 | $2.19 | $2.11 | $2.22 | $1.985 | 273,122 | 06-14-2024 |
$2.2 | $2.18 | $2.2 | $2.26 | $2.12 | 121,743 | 06-13-2024 |
$2.165 | $2.26 | $2.165 | $2.35 | $2.16 | 130,586 | 06-12-2024 |
$2.25 | $2.29 | $2.25 | $2.33 | $2.21 | 128,621 | 06-11-2024 |
$2.29 | $2.24 | $2.29 | $2.33 | $2.19 | 152,241 | 06-10-2024 |
News, Short Squeeze, Breakout and More Instantly...
Leap Therapeutics Inc. Company Name:
LPTX Stock Symbol:
NASDAQ Market:
Leap Therapeutics Inc. Website:
Leap Therapeutics Reports First Quarter 2024 Financial Results PR Newswire CAMBRIDGE, Mass. , May 13, 2024 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today report...
Leap Therapeutics Announces $40 Million Private Placement PR Newswire Net proceeds, along with existing cash, cash equivalents, and marketable securities are expected to extend cash runway into Q2 2026 and enable expansion of DKN-01 DeFianCe clinical trial and development prog...
Leap Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results PR Newswire CAMBRIDGE, Mass. , March 18, 2024 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeut...